BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30013227)

  • 1. Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.
    Albers AE; Qian X; Kaufmann AM; Mytilineos D; Ferris RL; Hoffmann TK; DeLeo AB
    Sci Rep; 2018 Jul; 8(1):10716. PubMed ID: 30013227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
    Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
    Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 as an immunotherapeutic target in head and neck cancer.
    Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
    Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
    Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
    Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
    Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
    Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
    Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
    Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
    Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL
    Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.
    Röpke M; Hald J; Guldberg P; Zeuthen J; Nørgaard L; Fugger L; Svejgaard A; Van der Burg S; Nijman HW; Melief CJ; Claesson MH
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14704-7. PubMed ID: 8962118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.
    Sirianni N; Ha PK; Oelke M; Califano J; Gooding W; Westra W; Whiteside TL; Koch WM; Schneck JP; DeLeo A; Ferris RL
    Clin Cancer Res; 2004 Oct; 10(20):6929-37. PubMed ID: 15501971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
    Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI
    Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of specific T cells for 264-272 and 149-157 peptides of p53 protein in peripheral blood of patients with breast cancer].
    Alvarez-Busto I; Albers A; Visus MC; Mayordomo JI; Sanz J; Burillo MA; Güemes A; García-Prats MD; Moros M; De Leo A; Tres A
    Med Clin (Barc); 2008 Nov; 131(18):685-8. PubMed ID: 19087825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.
    Chikamatsu K; Nakano K; Storkus WJ; Appella E; Lotze MT; Whiteside TL; DeLeo AB
    Clin Cancer Res; 1999 Jun; 5(6):1281-8. PubMed ID: 10389910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma.
    Schuler PJ; Boeckers P; Engers R; Boelke E; Bas M; Greve J; Dumitru CA; Lehnerdt GF; Ferris RL; Andrade Filho PA; Brandau S; Lang S; Whiteside TL; Hoffmann TK
    J Transl Med; 2011 Oct; 9():168. PubMed ID: 21970318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ T helper responses in squamous cell carcinoma of the head and neck.
    Chikamatsu K; Sakakura K; Yamamoto T; Furuya N; Whiteside TL; Masuyama K
    Oral Oncol; 2008 Sep; 44(9):870-7. PubMed ID: 18221909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.
    Andrade Filho PA; Ito D; Deleo AB; Ferris RL
    Cancer Immunol Immunother; 2010 Oct; 59(10):1561-8. PubMed ID: 20577877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.
    Hilburger Ryan M; Abrams SI
    Cancer Immunol Immunother; 2001 Jan; 49(11):603-12. PubMed ID: 11225991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.